End Stage Renal Failure on Dialysis Clinical Trial
— RAVASCOfficial title:
Long Term Outcomes of Cold Stored Venous Allografts in Vascular Access for Hemodialysis
NCT number | NCT04446546 |
Other study ID # | 2020PI096 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2014 |
Est. completion date | May 30, 2020 |
Verified date | June 2020 |
Source | Central Hospital, Nancy, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Vascular access creation in patients with renal failure requiring long-term hemodialysis can
be a challenge when there is no more autologous material or in case of infection, in a
population undergoing long term dialysis with a longer life-expectancy. Many types of grafts
have been used, with its advantages and drawbacks, such as prosthetic grafts (PTFE). Over the
past decade, surgeons have used cold stored venous allografts as a biological conduit for
hemodialysis, with the idea of avoiding most of major complications including a lower
incidence of infection and steal syndrome, with patencies at least equivalent to PTFE. There
is only a few data in the litterature, but many surgical teams use it when there is no
autologous material or in case of infection.
The aim of the study is to give the primary patency of vascular access with this technique,
and to assess its long term outcomes.
Status | Completed |
Enrollment | 120 |
Est. completion date | May 30, 2020 |
Est. primary completion date | December 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - End stage renal failure patient requiring hemodialysis - With the placement of a venous allograft for a hemodialysis approach - Who underwent a surgery between January 1, 2014 and December 31, 2018 in a vascular surgery department participating in our study Exclusion Criteria: - Patient <18 years old, or under guardianship / curatorship - Patient objecting to the use of his personal data in the context of research |
Country | Name | City | State |
---|---|---|---|
France | Departement of Vascular Surgery Nancy University Hospital | Nancy | Lorraine |
Lead Sponsor | Collaborator |
---|---|
Central Hospital, Nancy, France |
France,
Berardinelli L. Grafts and graft materials as vascular substitutes for haemodialysis access construction. Eur J Vasc Endovasc Surg. 2006 Aug;32(2):203-11. Epub 2006 Feb 20. Review. — View Citation
Heintjes RJ, Eikelboom BC, Steijling JJ, van Reedt Dortland RW, van der Heijden FH, Bastini M, van der Graaf Y, Blankestijn PJ, Vos J. The results of denatured homologous vein grafts as conduits for secondary haemodialysis access surgery. Eur J Vasc Endovasc Surg. 1995 Jan;9(1):58-63. — View Citation
Nedved K, Suchý T, Hálová J, Malický M, Gorun P, Vitvar P. Allogenous vein graft as vascular access for hemodialysis--lost battle? J Vasc Access. 2012 Jul-Sep;13(3):366-73. doi: 10.5301/jva.5000062. — View Citation
Schmidli J, Widmer MK, Basile C, de Donato G, Gallieni M, Gibbons CP, Haage P, Hamilton G, Hedin U, Kamper L, Lazarides MK, Lindsey B, Mestres G, Pegoraro M, Roy J, Setacci C, Shemesh D, Tordoir JHM, van Loon M, Esvs Guidelines Committee, Kolh P, de Borst GJ, Chakfe N, Debus S, Hinchliffe R, Kakkos S, Koncar I, Lindholt J, Naylor R, Vega de Ceniga M, Vermassen F, Verzini F, Esvs Guidelines Reviewers, Mohaupt M, Ricco JB, Roca-Tey R. Editor's Choice - Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018 Jun;55(6):757-818. doi: 10.1016/j.ejvs.2018.02.001. Epub 2018 May 2. — View Citation
Schneider M, Barrou B, Cluzel P, Hamani A, Bitker MO, Richard F. [Value of preserved saphenous vein graft for the creation of access ports in hemodialyzed patients: report of 309 cases]. Prog Urol. 2003 Sep;13(4):585-91. French. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Early and late complications (in days) | The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) | 30 days | |
Other | Early and late complications (in days) | The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) | 90 days | |
Other | Early and late complications (in days) | The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) | 6 months | |
Other | Early and late complications (in days) | The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) | 1 year | |
Other | Early and late complications (in days) | The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) | 2 years | |
Other | Early and late complications (in days) | The interval in days between the vascular access creation and the occurence of complications (stenosis, thrombosis, failure, hyperflow, distal ischemia, aneurysm) | 3 years | |
Other | Incidence of the socio-demographic and clinical characteristics of the patients on secondary patency | Compare the duration of secondary patency according to the socio-demographic and clinical characteristics of the patients | 3 years | |
Primary | Intervention free vascular access survival (in days) | The interval in days between the vascular access creation and the first successful re intervention (primary patency) | 30 days | |
Primary | Intervention free vascular access survival (in days) | The interval in days between the vascular access creation and the first successful re intervention (primary patency) | 6 months | |
Primary | Intervention free vascular access survival (in days) | The interval in days between the vascular access creation and the first successful re intervention (primary patency) | 1 year | |
Primary | Intervention free vascular access survival (in days) | The interval in days between the vascular access creation and the first successful re intervention (primary patency) | 2 years | |
Primary | Intervention free vascular access survival (in days) | The interval in days between the vascular access creation and the first successful re intervention (primary patency) | 3 years | |
Secondary | Thrombosis free vascular access survival (in days) | The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) | 30 days | |
Secondary | Thrombosis free vascular access survival (in days) | The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) | 90 days | |
Secondary | Thrombosis free vascular access survival (in days) | The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) | 6 months | |
Secondary | Thrombosis free vascular access survival (in days) | The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) | 1 year | |
Secondary | Thrombosis free vascular access survival (in days) | The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) | 2 years | |
Secondary | Thrombosis free vascular access survival (in days) | The interval in days between the vascular access creation and the first occlusion with a successful re intervention (primary assisted pantency) | 3 years | |
Secondary | Abandonment of the vascular access (in days) | The interval in days between the vascular access creation and its abandonment (secondary patency) | 30 days | |
Secondary | Abandonment of the vascular access (in days) | The interval in days between the vascular access creation and its abandonment (secondary patency) | 90 days | |
Secondary | Abandonment of the vascular access (in days) | The interval in days between the vascular access creation and its abandonment (secondary patency) | 6 months | |
Secondary | Abandonment of the vascular access (in days) | The interval in days between the vascular access creation and its abandonment (secondary patency) | 1 year | |
Secondary | Abandonment of the vascular access (in days) | The interval in days between the vascular access creation and its abandonment (secondary patency) | 2 years | |
Secondary | Abandonment of the vascular access (in days) | The interval in days between the vascular access creation and its abandonment (secondary patency) | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04103177 -
Physical Activity in Haemodialysis Patients: a Feasibility Study
|
N/A | |
Completed |
NCT01561118 -
DiaSport - Endurance-orientated Training Program With Children and Adolescents on Maintenance Hemodialysis
|
N/A | |
Withdrawn |
NCT03645720 -
The Prognosis of Graft Using Plastic Cannula in Hemodialysis
|
N/A | |
Active, not recruiting |
NCT02598635 -
Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis
|
Phase 4 | |
Terminated |
NCT01643733 -
Study on Fistuloplasty Using Flow Measurement Guidance
|
N/A | |
Not yet recruiting |
NCT03169400 -
Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)
|
N/A | |
Completed |
NCT02439697 -
A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients
|
N/A | |
Completed |
NCT02063490 -
Nurse-led Intervention to Improve Phosphate Binder Adherence
|
N/A | |
Completed |
NCT04106310 -
Theranova vs High-flux HD Comparison
|
N/A | |
Recruiting |
NCT06056102 -
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
|
Phase 1 | |
Completed |
NCT04698512 -
MAgicTouchâ„¢ Intervention Leap for Dialysis Access (MATILDA) Trial
|
||
Completed |
NCT02819011 -
OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO
|
Phase 2 | |
Completed |
NCT02484118 -
Hemodialysis Blood Flow and Urea Clearance
|
N/A | |
Enrolling by invitation |
NCT01641757 -
Effect of Non-Surgical Periodontal Therapy on Serum Albumin Levels of Patients on Maintenance Hemodialysis Therapy,
|
Phase 2 | |
Completed |
NCT03172039 -
Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit
|
N/A | |
Completed |
NCT03897231 -
Prevalence of Non-adherence to Medication Among Patients on Chronic Hemodialysis
|
||
Withdrawn |
NCT03145662 -
High Pressure Balloon vs Cutting Balloon
|
N/A | |
Completed |
NCT02621918 -
The Effects of Exercise in End-stage Renal Disease Patients Undergoing Hemodialysis
|
N/A | |
Completed |
NCT01356615 -
Low Molecular Weight Heparin for Hemodialysis Anticoagulation
|
N/A | |
Terminated |
NCT01033357 -
Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access
|
N/A |